Eisai Co., Ltd.’s partnership with Bristol Myers Squibb Company on the antibody-drug conjugate farletuzumab ecteribulin (FZEC) appears to be a casualty of Bristol’s R&D prioritization program. Eisai announced the end of the three-year partnership on FZEC, formerly known as MORAb-202, on 1 July and said it plans to accelerate development of the product and conduct development and commercialization independently.
Key Takeaways
- Eisai plans to accelerate development of farletuzumab ecteribulin after regaining full rights from Bristol Myers Squibb.
- Farletuzumab ecteribulin is a folate receptor alpha (FRα)-targeting ADC in development for ovarian and other cancers, but is behind rivals, including AbbVie’s marketed Elahere
Bristol paid handsomely for rights to co-develop and co-commercialize FZEC in regions including the US, Europe and Asia in 2021. (Also see "BMS, Eisai Team Up To Accelerate Development Of Solid-Tumor ADC" - Scrip, 18 June, 2021
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
